Novartis | NOVN - Operating Profit

Stock Price
119.50
Daily Change
-2.28 -1.87%
Monthly
-5.52%
Yearly
21.64%
Q1 Forecast
118.31

Novartis reported $4.5B in Operating Profit for its fiscal quarter ending in September of 2025.





Operating Profit Change Date
AbbVie USD 5.81B 1.23B Dec/2025
Alcon AG USD 313M 19M Dec/2025
Almirall EUR 30.23M 12.8M Dec/2025
Amgen USD 3.96B 464M Dec/2025
AstraZeneca USD 2.97B 4.48B Dec/2025
Autolus Therapeutics Ltd USD -71.62M 10.99M Sep/2025
Bayer EUR 1.11B 1.65B Dec/2025
Biogen USD 659.6M 192.2M Sep/2025
Bristol-Myers Squibb USD 4.2B 562M Dec/2025
Eli Lilly USD 8.99B 599.9M Dec/2025
Fresenius EUR 713M 139M Dec/2025
Fresenius Medical Care EUR 663M 213.06M Dec/2025
Galapagos EUR 780.56M 822.23M Dec/2025
Genmab DKK 360M 172M Jun/2025
Gilead Sciences USD 2.96B 551M Dec/2025
GlaxoSmithKline GBP 1.44B 1.35B Dec/2025
GRIFOLS EUR 275.38M 76.74M Dec/2025
Hikma Pharmaceutical USD 348M 161M Dec/2025
J&J USD 5.59B 1.81B Dec/2025
Lonza CHF 430M 104M Dec/2024
Merck EUR 474M 738M Dec/2025
Merck USD 6.24B 318M Dec/2025
Novartis USD 4.5B 363M Sep/2025
Novartis USD 4.58B 879M Sep/2025
Novo Nordisk DKK 32.38B 1.7B Dec/2025
Orion EUR 328.2M 207.2M Dec/2025
Pfizer USD 4.65B 3.99B Dec/2025
Philips EUR 719M 390M Dec/2025
Recordati EUR 278.23M 112.58M Dec/2025
Regeneron Pharmaceuticals USD 898.6M 211.3M Dec/2025
Roche Holding CHF 9.56B 3.8B Dec/2025
Sanofi EUR 1.7B 2.17B Dec/2025
UCB EUR 1B 678M Dec/2024